Using microarray expression studies of breast tumors across multiple patient cohorts, we found that ZNF217 expression levels are higher in ER+ tumors than in ER- tumors (data-mining from the Chin 2006 [36] and the Hess 2006 [37] studies are shown in Figure 6A and B). This evidence concerns the gene ZNF217 and breast neoplasm.